EFFECTIVENESS OF DOCETAXEL IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER IN THE FIRST TREATMENT LINE

被引：0
|
作者：
Villa, J. C. [1 ]
Espinosa, J. [1 ]
Gomez, R. [1 ]
Sanchez, V [1 ]
Lopez, R. [1 ]
Galan, R. [1 ]
Pineda, M. D. [1 ]
Perez, M. [1 ]
机构：
[1] Ciudad Real Univ Gen Hosp, Ciudad Real, Spain
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.236
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN8
引用
收藏
页码：A816 / A817
页数：2
相关论文
共 50 条
  • [41] γ-Klotho is correlated with resistance to docetaxel in castration-resistant prostate cancer
    Onishi, Kenta
    Miyake, Makito
    Hori, Shunta
    Onishi, Sayuri
    Iida, Kota
    Morizawa, Yosuke
    Tatsumi, Yoshihiro
    Nakai, Yasushi
    Tanaka, Nobumichi
    Fujimoto, Kiyohide
    ONCOLOGY LETTERS, 2020, 19 (03) : 2306 - 2316
  • [42] Survival outcome in patients with metastatic castration-resistant prostate cancer according to first-line treatment.
    Gross-Goupil, Marine
    Thurin, Nicolas H.
    Rouyer, Magali
    Jove, Jeremy
    Haaser, Thibaud
    Rebillard, Xavier
    Soulie, Michel
    de Pouvourville, Gerard
    Pierres, Marie
    Capone, Camille
    Lamarque, Stephanie
    Bignon, Emmanuelle
    Droz-Perroteau, Cecile
    Moore, Nicholas
    Blin, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [43] PSA surge in patients with castration-resistant prostate cancer receiving docetaxel.
    Tabata, Ken-ichi
    Satoh, Takefumi
    Matsumoto, Kazumasa
    Fujita, Tetsuo
    Iwamura, Masatsugu
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [44] Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial
    Caffo, Orazio
    Ortega, Cinzia
    Nole, Franco
    Gasparro, Donatello
    Mucciarini, Claudia
    Aieta, Michele
    Zagonel, Vittorina
    Iacovelli, Roberto
    De Giorgi, Ugo
    Facchini, Gaetano
    Veccia, Antonello
    Palesandro, Erica
    Verri, Elena
    Buti, Sebastiano
    Razzini, Giorgia
    Bozza, Giovanni
    Maruzzo, Marco
    Ciccarese, Chiara
    Schepisi, Giuseppe
    Rossetti, Sabrina
    Maines, Francesca
    Kinspergher, Stefania
    Fratino, Lucia
    Ermacora, Paola
    Nicodemo, Maurizio
    Giordano, Monica
    Sartori, Donata
    Scapoli, Daniela
    Sabbatini, Roberto
    Lo Re, Giovanni
    Morelli, Franco
    D'Angelo, Alessandro
    Vittimberga, Isabella
    Lippe, Paolo
    Carrozza, Francesco
    Messina, Caterina
    Galli, Luca
    Valcamonico, Francesca
    Porta, Camillo
    Pappagallo, Giovanni
    Aglietta, Massimo
    EUROPEAN JOURNAL OF CANCER, 2021, 155 : 56 - 63
  • [45] Prognostic impact of pre-treatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel
    Buttigliero, C.
    Tucci, M.
    Vignani, F.
    Pisano, C.
    Bertaglia, V.
    Pignataro, D.
    Bironzo, P.
    Guglielmini, P. F.
    Scagliotti, G. V.
    Di Maio, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [46] Docetaxel with or without zoledronic acid for castration-resistant prostate cancer
    Yue Pan
    Haiyong Jin
    Wei Chen
    Zhixian Yu
    Tingyu Ye
    Yuancai Zheng
    Zhiliang Weng
    Feng Wang
    International Urology and Nephrology, 2014, 46 : 2319 - 2326
  • [47] Docetaxel with or without zoledronic acid for castration-resistant prostate cancer
    Pan, Yue
    Jin, Haiyong
    Chen, Wei
    Yu, Zhixian
    Ye, Tingyu
    Zheng, Yuancai
    Weng, Zhiliang
    Wang, Feng
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2014, 46 (12) : 2319 - 2326
  • [48] PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China
    Wu, Kai-Jie
    Pei, Xin-Qi
    Tian, Ge
    Wu, Da-Peng
    Fan, Jin-Hai
    Jiang, Yu-Mei
    He, Da-Lin
    ASIAN JOURNAL OF ANDROLOGY, 2018, 20 (02) : 173 - 177
  • [49] Docetaxel in combination with estramustine and prednisolone for castration-resistant prostate cancer
    Tomomi Kuramoto
    Takeshi Inagaki
    Reona Fujii
    Yumiko Sasaki
    Satoshi Nishizawa
    Yoshihito Nanpo
    Nagahide Matusmura
    Yasuo Kohjimoto
    Isao Hara
    International Journal of Clinical Oncology, 2013, 18 : 890 - 897
  • [50] Cost-effectiveness evaluation of abiraterone in the treatment of patients with castration-resistant prostate cancer who previously received docetaxel.
    Chopra, Akhil
    Gluck, Stefan
    Montero, Alberto J.
    Avancha, Kiran Kumar Venkata Raja
    Lopes, Gilberto
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345